Clinical Adoption of Prognostic Biomarkers: The Case for Heart Failure

Progress in Cardiovascular Diseases

Volumn 55, Issue 1, 2012, Pages 3-13

  Kalogeropoulos, Andreas P ^a   Georgiopoulou, Vasiliki V ^a   Butler, Javed ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

Biomarkers; Heart failure; Prognosis; Risk prediction

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; COLLAGEN; COPEPTIN; CYSTATIN C; ENDOTHELIN 1; MYELOPEROXIDASE; PROADRENOMEDULLIN; ROSUVASTATIN; SPIRONOLACTONE; TROPONIN I; TROPONIN T;

ARTICLE; BIOLOGICAL MONITORING; CARDIAC PATIENT; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVASCULAR RISK; CLINICAL DECISION MAKING; CLINICAL EVALUATION; CLINICAL TRIAL (TOPIC); DEFIBRILLATOR; DISEASE CLASSIFICATION; DRUG TARGETING; HEART FAILURE; HEART TRANSPLANTATION; HUMAN; LEFT VENTRICULAR ASSIST DEVICE; PREDICTION; PROGNOSIS; TREATMENT OUTCOME;

BIOLOGICAL MARKERS; DECISION SUPPORT TECHNIQUES; EVIDENCE-BASED MEDICINE; HEART FAILURE; HUMANS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS;

EID: 84864044116     PISSN: 00330620     EISSN: 18731740     Source Type: Journal    
DOI: 10.1016/j.pcad.2012.05.004     Document Type: Article

References (86)

1. Jessup M., Abraham W.T., Casey D.E., et al. 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009, 119:1977-2016.
2. Barth A.S., Chakir K., Kass D.A., et al. Transcriptome, proteome, and metabolome in dyssynchronous heart failure and CRT. J Cardiovasc Transl Res 2012, 5:180-187.
3. Tang W.H.W., Francis G.S., Morrow D.A., et al. National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: clinical utilization of cardiac biomarker testing in heart failure. Circulation 2007, 116:e99-e109.
4. Morrow D.A., de Lemos J.A. Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation 2007, 115:949-952.
5. Maisel A. Biomonitoring and biomarker-guided therapy: the next step in heart failure and biomarker research. J Am Coll Cardiol 2011, 58:1890-1892.
6. Hlatky M.A., Greenland P., Arnett D.K., et al. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation 2009, 119:2408-2416.
7. van Kimmenade R.R.J., Januzzi J.L. Emerging biomarkers in heart failure. Clin Chem 2012, 58:127-138.
8. Ky B., French B., Levy W.C., et al. Multiple biomarkers for risk prediction in chronic heart failure. Circ Heart Fail 2012, 5:183-190.
9. Rauchhaus M., Doehner W., Francis D.P., et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 2000, 102:3060-3067.
10. Subramanian D., Subramanian V., Deswal A., et al. New predictive models of heart failure mortality using time-series measurements and ensemble models. Circ Heart Fail 2011, 4:456-462.
11. Ma L.-P., Haugen E., Ikemoto M., et al. S100A8/A9 complex as a new biomarker in prediction of mortality in elderly patients with severe heart failure. Int J Cardiol 2012, 155:26-32.
12. Gerber Y., Dunlay S.M., Jaffe A.S., et al. Plasma lipoprotein-associated phospholipase A2 levels in heart failure: association with mortality in the community. Atherosclerosis 2009, 203:593-598.
13. Bilim O., Takeishi Y., Kitahara T., et al. Serum YKL-40 predicts adverse clinical outcomes in patients with chronic heart failure. J Card Fail 2010, 16:873-879.
14. Chorianopoulos E., Rosenberg M., Zugck C., et al. Decreased soluble TWEAK levels predict an adverse prognosis in patients with chronic stable heart failure. Eur J Heart Fail 2009, 11:1050-1056.
15. Kitahara T., Shishido T., Suzuki S., et al. Serum midkine as a predictor of cardiac events in patients with chronic heart failure. J Card Fail 2010, 16:308-313.
16. Suzuki S., Takeishi Y., Niizeki T., et al. Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure. Am Heart J 2008, 155:75-81.
17. Kotooka N., Inoue T., Aoki S., et al. Prognostic value of pentraxin 3 in patients with chronic heart failure. Int J Cardiol 2008, 130:19-22.
18. Monteiro S., Franco F., Costa S., et al. Prognostic value of CA125 in advanced heart failure patients. Int J Cardiol 2010, 140:115-118.
19. Ueland T., Jemtland R., Godang K., et al. Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. J Am Coll Cardiol 2004, 44:1970-1976.
20. Røysland R., Masson S., Omland T., et al. Prognostic value of osteoprotegerin in chronic heart failure: the GISSI-HF trial. Am Heart J 2010, 160:286-293.
21. Kistorp C., Faber J., Galatius S., et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 2005, 112:1756-1762.
22. Tang W.H.W., Tong W., Troughton R.W., et al. Prognostic value and echocardiographic determinants of plasma myeloperoxidase levels in chronic heart failure. J Am Coll Cardiol 2007, 49:2364-2370.
23. Tsutsui T., Tsutamoto T., Wada A., et al. Plasma oxidized low-density lipoprotein as a prognostic predictor in patients with chronic congestive heart failure. J Am Coll Cardiol 2002, 39:957-962.
24. Radauceanu A., Ducki C., Virion J.-M., et al. Extracellular matrix turnover and inflammatory markers independently predict functional status and outcome in chronic heart failure. J Card Fail 2008, 14:467-474.
25. Lopez-Andrès N., Rossignol P., Iraqi W., et al. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial. Eur J Heart Fail 2012, 14:74-81.
26. Frantz S., Störk S., Michels K., et al. Tissue inhibitor of metalloproteinases levels in patients with chronic heart failure: an independent predictor of mortality. Eur J Heart Fail 2008, 10:388-395.
27. Bhalla V., Georgiopoulou V.V., Azeem A.A., et al. Matrix metalloproteinases, tissue inhibitors of metalloproteinases, and heart failure outcomes. Int J Cardiol 2011, 151:237-239.
28. Zannad F., Alla F., Dousset B., et al. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation 2000, 102:2700-2706.
29. Lok D.J.A., Van Der Meer P., de la Porte P.W.B.-A., et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol 2010, 99:323-328.
30. Shah R.V., Chen-Tournoux A.A., Picard M.H., et al. Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. Eur J Heart Fail 2010, 12:826-832.
31. Cohn J.N., Johnson G.R., Shabetai R., et al. Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure. The V-HeFT VA Cooperative Studies Group. Circulation 1993, 87:VI5-VI16.
32. Latini R., Masson S., Anand I., et al. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J 2004, 25:292-299.
33. Pacher R., Stanek B., Hülsmann M., et al. Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J Am Coll Cardiol 1996, 27:633-641.
34. Alehagen U., Dahlström U., Rehfeld J.F., et al. Association of copeptin and N-terminal proBNP concentrations with risk of cardiovascular death in older patients with symptoms of heart failure. JAMA 2011, 305:2088-2095.
35. Peacock W.F., Nowak R., Christenson R., et al. Short-term mortality risk in emergency department acute heart failure. Acad Emerg Med 2011, 18:947-958.
36. Tentzeris I., Jarai R., Farhan S., et al. Complementary role of copeptin and high-sensitivity troponin in predicting outcome in patients with stable chronic heart failure. Eur J Heart Fail 2011, 13:726-733.
37. Masson S., Latini R., Carbonieri E., et al. The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data from the GISSI-heart failure (GISSI-HF) trial. Eur J Heart Fail 2010, 12:338-347.
38. Adlbrecht C., Hülsmann M., Strunk G., et al. Prognostic value of plasma midregional pro-adrenomedullin and C-terminal-pro-endothelin-1 in chronic heart failure outpatients. Eur J Heart Fail 2009, 11:361-366.
39. Røsjø H., Masson S., Latini R., et al. Prognostic value of chromogranin A in chronic heart failure: data from the GISSI-Heart Failure trial. Eur J Heart Fail 2010, 12:549-556.
40. Maisel A., Mueller C., Nowak R., et al. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol 2010, 55:2062-2076.
41. Dunlay S.M., Gerber Y., Weston S.A., et al. Prognostic value of biomarkers in heart failure: application of novel methods in the community. Circ Heart Fail 2009, 2:393-400.
42. Pascual-Figal D.A., Manzano-Fernández S., Boronat M., et al. Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure. Eur J Heart Fail 2011, 13:718-725.
43. Arimoto T., Takeishi Y., Niizeki T., et al. Cardiac sympathetic denervation and ongoing myocardial damage for prognosis in early stages of heart failure. J Card Fail 2007, 13:34-41.
44. Niessner A., Hohensinner P.J., Rychli K., et al. Prognostic value of apoptosis markers in advanced heart failure patients. Eur Heart J 2009, 30:789-796.
45. Felker G.M., Hasselblad V., Hernandez A.F., et al. Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. Am Heart J 2009, 158:422-430.
46. Eurlings L.W.M., van Pol P.E.J., Kok W.E., et al. Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: results of the PRIMA (Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality?) study. J Am Coll Cardiol 2010, 56:2090-2100.
47. Adlbrecht C., Huelsmann M., Berger R., et al. Cost analysis and cost-effectiveness of NT-proBNP-guided heart failure specialist care in addition to home-based nurse care. Eur J Clin Invest 2011, 41:315-322.
48. Bayes-Genis A., de Antonio M., Galán A., et al. Combined use of high-sensitivity ST2 and NTproBNP to improve the prediction of death in heart failure. Eur J Heart Fail 2012, 14:32-38.
49. Ky B., French B., McCloskey K., et al. High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circ Heart Fail 2011, 4:180-187.
50. Kempf T., von Haehling S., Peter T., et al. Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. J Am Coll Cardiol 2007, 50:1054-1060.
51. Anand I.S., Kempf T., Rector T.S., et al. Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial. Circulation 2010, 122:1387-1395.
52. Ky B., Kimmel S.E., Safa R.N., et al. Neuregulin-1 beta is associated with disease severity and adverse outcomes in chronic heart failure. Circulation 2009, 120:310-317.
53. Manzano-Fernández S., Januzzi J.L., Boronat-Garcia M., et al. β-trace protein and cystatin C as predictors of long-term outcomes in patients with acute heart failure. J Am Coll Cardiol 2011, 57:849-858.
54. Damman K., Masson S., Hillege H.L., et al. Clinical outcome of renal tubular damage in chronic heart failure. Eur Heart J 2011, 32:2705-2712.
55. Maisel A.S., Mueller C., Fitzgerald R., et al. Prognostic utility of plasma neutrophil gelatinase-associated lipocalin in patients with acute heart failure: the NGAL EvaLuation Along with B-type NaTriuretic Peptide in acutely decompensated heart failure (GALLANT) trial. Eur J Heart Fail 2011, 13:846-851.
56. Tsutamoto T., Wada A., Maeda K., et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997, 96:509-516.
57. Carrasco-Sánchez F.J., Galisteo-Almeda L., Páez-Rubio I., et al. Prognostic value of cystatin C on admission in heart failure with preserved ejection fraction. J Card Fail 2011, 17:31-38.
58. Ather S., Chan W., Bozkurt B., et al. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol 2012, 59:998-1005.
59. Krum H., Elsik M., Schneider H.G., et al. Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy. Circ Heart Fail 2011, 4:561-568.
60. Biolo A., Fisch M., Balog J., et al. Episodes of acute heart failure syndrome are associated with increased levels of troponin and extracellular matrix markers. Circ Heart Fail 2010, 3:44-50.
61. Heidenreich P.A., Hernandez A.F., Yancy C.W., et al. Get With The Guidelines program participation, process of care, and outcome for Medicare patients hospitalized with heart failure. Circ Cardiovasc Qual Outcomes 2012, 5:37-43.
62. Bristow M.R., Saxon L.A., Boehmer J., et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004, 350:2140-2150.
63. Maisel A., Xue Y., Shah K., et al. Increased 90-day mortality in patients with acute heart failure with elevated copeptin: secondary results from the Biomarkers in Acute Heart Failure (BACH) study. Circ Heart Fail 2011, 4:613-620.
64. Philbin E.F., Dec G.W., Jenkins P.L., et al. Socioeconomic status as an independent risk factor for hospital readmission for heart failure. Am J Cardiol 2001, 87:1367-1371.
65. Foraker R.E., Rose K.M., Suchindran C.M., et al. Socioeconomic status, Medicaid coverage, clinical comorbidity, and rehospitalization or death after an incident heart failure hospitalization: Atherosclerosis Risk in Communities cohort (1987 to 2004). Circ Heart Fail 2011, 4:308-316.
66. Joynt K.E., Jha A.K. Thirty-day readmissions-truth and consequences. N Engl J Med 2012, 366:1366-1369.
67. Giamouzis G., Kalogeropoulos A., Georgiopoulou V., et al. Hospitalization epidemic in patients with heart failure: risk factors, risk prediction, knowledge gaps, and future directions. J Card Fail 2011, 17:54-75.
68. Pencina M.J., D'Agostino R.B., D'Agostino R.B., et al. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008, 27:157-172. [discussion 207-212].
69. Kociol R.D., Horton J.R., Fonarow G.C., et al. Admission, discharge, or change in B-type natriuretic peptide and long-term outcomes: data from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF) linked to Medicare claims. Circ Heart Fail 2011, 4:628-636.
70. Mancini D., Lietz K. Selection of cardiac transplantation candidates in 2010. Circulation 2010, 122:173-183.
71. Dickstein K., Vardas P.E., Auricchio A., et al. 2010 Focused Update of ESC Guidelines on device therapy in heart failure: an update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. Eur Heart J 2010, 31:2677-2687.
72. Pascual-Figal D.A., Ordoñez-Llanos J., Tornel P.L., et al. Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction. J Am Coll Cardiol 2009, 54:2174-2179.
73. Aarones M., Gullestad L., Aakhus S., et al. Prognostic value of cardiac troponin T in patients with moderate to severe heart failure scheduled for cardiac resynchronization therapy. Am Heart J 2011, 161:1031-1037.
74. Zile M.R., Gaasch W.H., Anand I.S., et al. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. Circulation 2010, 121:1393-1405.
75. Holland D.J., Kumbhani D.J., Ahmed S.H., et al. Effects of treatment on exercise tolerance, cardiac function, and mortality in heart failure with preserved ejection fraction. A meta-analysis. J Am Coll Cardiol 2011, 57:1676-1686.
76. Anand I.S., Rector T.S., Cleland J.G., et al. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Circ Heart Fail 2011, 4:569-577.
77. O'Connor C.M., Fiuzat M., Lombardi C., et al. Impact of serial troponin release on outcomes in patients with acute heart failure: analysis from the PROTECT pilot study. Circ Heart Fail 2011, 4:724-732.
78. Xue Y., Clopton P., Peacock W.F., et al. Serial changes in high-sensitive troponin I predict outcome in patients with decompensated heart failure. Eur J Heart Fail 2011, 13:37-42.
79. Metra M., Bettari L., Pagani F., et al. Troponin T levels in patients with acute heart failure: clinical and prognostic significance of their detection and release during hospitalisation. Clin Res Cardiol 2012, [Epub ahead of print].
80. Kawahara C., Tsutamoto T., Sakai H., et al. Prognostic value of serial measurements of highly sensitive cardiac troponin I in stable outpatients with nonischemic chronic heart failure. Am Heart J 2011, 162:639-645. [Epub ahead of print].
81. Masson S., Anand I., Favero C., et al. Serial measurement of cardiac troponin T using a highly sensitive assay in patients with chronic heart failure: data from 2 large randomized clinical trials. Circulation 2012, 125:280-288.
82. O'Donoghue M., Braunwald E. Natriuretic peptides in heart failure: should therapy be guided by BNP levels?. Nat Rev Cardiol 2010, 7:13-20.
83. Mant J., Al-Mohammad A., Swain S., et al. Management of chronic heart failure in adults: synopsis of the National Institute For Health and clinical excellence guideline. Ann Intern Med 2011, 155:252-259.
84. Taub P.R., Gabbai-Saldate P., Maisel A. Biomarkers of heart failure. Congest Heart Fail 2010, 16(Suppl. 1):S19-S24.
85. McMurray J.J., Kjekshus J., Gullestad L., et al. Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis. Circulation 2009, 120:2188-2196.
86. Ahmad T., Fiuzat M., Felker G.M., et al. Novel biomarkers in chronic heart failure. Nat Rev Cardiol 2012, 9:347-359.